NEW YORK--(BUSINESS WIRE)--Dell today announced a major commitment of funding, employee engagement and cloud computing technology to support pediatric cancer research programs globally, including the world’s first personalized medicine trial for pediatric cancer conducted by the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) and supported by The Translational Genomics Research Institute (TGen). TGen will use its genomic technology within Dell’s donated cloud to help NMTRC identify a greater depth of personalized treatment strategies for children with neuroblastoma who are enrolled in NMTRC’s clinical trial.
